• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hong Kong Journal of Paediatrics >Institutional Experience of Five-day Courses of Irinotecan as Palliative Chemotherapy in Chinese Patients with Refractory Neuroblastoma
【24h】

Institutional Experience of Five-day Courses of Irinotecan as Palliative Chemotherapy in Chinese Patients with Refractory Neuroblastoma

机译：中国难治性神经母细胞瘤患者伊立替康五天疗程作为姑息化疗的机构经验

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To evaluate the efficacy, safety and quality of life of irinotecan in Chinese refractory neuroblastoma patients in affiliated hospitals of China Medical University. Patients and Methods: Seven patients received irinotecan at 40-50 mg/m2/day administered as a 60-minute infusion for 5 consecutive days, every 3 weeks. Tumour response, toxicities and performance status were evaluated. Results: Stable disease was observed in 3 of 7 patients (42.9%). Most common grade 3-4 toxicities were myelosuppressive haematologic toxicities. Grade 1-2 nausea, vomiting, abdominal pain, or cramping and diarrhoea were the most common non-haematologic drug-related toxicities observed. Quality of life was improved in almost all patients. Conclusion: Irinotecan as a single agent was well tolerated and was a very safe regimen in Chinese patients. Although this regimen induced no objective response (CR+PR) in refractory neuroblastoma patients, the clinical benefit rate (CR+PR+SD) was 42.9%. This regimen could alleviate pain and to some extent improve the quality of life for heavily pretreated refractory Chinese neuroblastoma patients.
机译：目的：评价伊立替康对中国医科大学附属医院难治性神经母细胞瘤患者的疗效，安全性和生活质量。患者与方法：7名患者每3周连续5天以40分钟输注的剂量接受40-50 mg / m 2 /天的伊立替康。评估肿瘤反应，毒性和生产状况。结果：7名患者中有3名（42.9％）观察到稳定的疾病。最常见的3-4级毒性是骨髓抑制性血液学毒性。 1-2级恶心，呕吐，腹痛或痉挛和腹泻是观察到的最常见的非血液学药物相关毒性。几乎所有患者的生活质量均得到改善。结论：伊立替康单药耐受性良好，在中国患者中是非常安全的方案。尽管该方案在难治性神经母细胞瘤患者中未引起客观反应（CR + PR），但临床受益率（CR + PR + SD）为42.9％。这种方案可以减轻疼痛，并在一定程度上改善严重预处理的难治性中国神经母细胞瘤患者的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号